Tanshinone II A stabilizes vulnerable plaques by suppressing RAGE signaling and NF-κB activation in apolipoprotein-E-deficient mice

Zhao,Dong; Tong,Lufang; Zhang,Lixin; Li,Hong; Wan,Yingxin; Zhang,Tiezhong

doi:10.3892/mmr.2016.5916

Tanshinone II A stabilizes vulnerable plaques by suppressing RAGE signaling and NF-κB activation in apolipoprotein-E-deficient mice

Authors:
- Dong Zhao
- Lufang Tong
- Lixin Zhang
- Hong Li
- Yingxin Wan
- Tiezhong Zhang
View Affiliations

Affiliations: Department of Geriatric Medicine, China‑Japan Friendship Hospital, Beijing 100029, P.R. China, Department of Pharmacy, China‑Japan Friendship Hospital, Beijing 100029, P.R. China, Department of Dermatology, China‑Japan Friendship Hospital, Beijing 100029, P.R. China, Institute of Clinical Medical Sciences, China‑Japan Friendship Hospital, Beijing 100029, P.R. China, Third Department of Internal Medicine, Changping Chinese and Western Medicine Hospital, Beijing 102208, P.R. China
Published online on: November 1, 2016 https://doi.org/10.3892/mmr.2016.5916
Pages: 4983-4990
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tanshinone II A (TSIIA) is a diterpene quinone extracted from the roots of Salvia miltiorrhiza with anti-inflammatory and anti‑oxidant properties that is used to treat atherosclerosis. In the current study, morphological analyses were conducted to evaluate the effects of TSIIA on atherosclerotic vulnerable plaque stability. Additionally, receptor of advanced glycation end products (RAGE), adhesion molecule, and matrix‑metalloproteinases (MMPs) expression, and nuclear factor-κB (NF‑κB) activation were examined in apolipoprotein E (apoE)‑deficient mice treated with TSIIA. Eight‑week‑old apoE-/- mice were administered TSIIA and fed an atherogenic diet for 8 weeks. TSIIA exhibited no effects on plaque size. Analysis of the vulnerable plaque composition demonstrated decreased numbers of macrophages and smooth muscle cells, and increased collagen content in apoE‑deficient mice treated with TSIIA compared with untreated mice. Western blotting revealed that TSIIA downregulated the expression levels of vascular cellular adhesion molecule-1 (VCAM-1), intercellular adhesion molecule‑1 (ICAM‑1), and MMP‑2, ‑3, and ‑9, suppressed RAGE, and inhibited NF‑κB, JNK and p38 activation. The present study demonstrated that the underlying mechanism of TSIIA stabilization of vulnerable plaques involves interfering with RAGE and NF‑κB activation, and downregulation of downstream inflammatory factors, including ICAM‑1, VCAM‑1, and MMP‑2, ‑3 and ‑9 in apoE-/- mice.

View Figures

View References

1	Burke AP, Kolodgie FD, Farb A, Weber D and Virmani R: Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation. 105:297–303. 2002. View Article : Google Scholar : PubMed/NCBI
2	Stoll G and Bendszus M: Inflammation and atherosclerosis: Novel insights into plaque formation and destabilization. Stroke. 37:1923–1932. 2006. View Article : Google Scholar : PubMed/NCBI
3	Newby AC, George SJ, Ismail Y, Johnson JL, Sala-Newby GB and Thomas AC: Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost. 101:1006–1011. 2009.PubMed/NCBI
4	Gough PJ, Gomez IG, Wille PT and Raines EW: Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest. 116:59–69. 2006. View Article : Google Scholar : PubMed/NCBI
5	Silence J, Lupu F, Collen D and Lijnen HR: Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol. 21:1440–1445. 2001. View Article : Google Scholar : PubMed/NCBI
6	Bäck M, Ketelhuth DF and Agewall S: Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis. 52:410–428. 2010. View Article : Google Scholar : PubMed/NCBI
7	Toutouzas K, Synetos A, Nikolaou C, Tsiamis E, Tousoulis D and Stefanadis C: Matrix metalloproteinases and vulnerable atheromatous plaque. Curr Top Med Chem. 12:1166–1180. 2012. View Article : Google Scholar : PubMed/NCBI
8	Berg G, Miksztowicz V and Schreier L: Metalloproteinases in metabolic syndrome. Clin Chim Acta. 412:1731–1739. 2011. View Article : Google Scholar : PubMed/NCBI
9	Sun L, Ishida T, Yasuda T, Kojima Y, Honjo T, Yamamoto Y, Yamamoto H, Ishibashi S, Hirata K and Hayashi Y: RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc Res. 82:371–381. 2009. View Article : Google Scholar : PubMed/NCBI
10	Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, Kalea AZ, Lu Y, Rosario RH, Oruganti S, et al: Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE^−/− mice. J Clin Invest. 118:183–194. 2008. View Article : Google Scholar : PubMed/NCBI
11	Zhang F, Banker G, Liu X, Suwanabol PA, Lengfeld J, Yamanouchi D, Kent KC and Liu B: The novel function of advanced glycation end products in regulation of MMP-9 production. J Surg Res. 171:871–876. 2011. View Article : Google Scholar : PubMed/NCBI
12	Goldin A, Beckman JA, Schmidt AM and Creager MA: Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation. 114:597–605. 2006. View Article : Google Scholar : PubMed/NCBI
13	Hoefen RJ and Berk BC: The role of MAP kinases in endothelial activation. Vascul Pharmacol. 38:271–273. 2002. View Article : Google Scholar : PubMed/NCBI
14	Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Klöting I, et al: Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 50:2792–2808. 2001. View Article : Google Scholar : PubMed/NCBI
15	Kutuk O and Basaga H: Inflammation meets oxidation: NF-kappaB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med. 9:549–557. 2003. View Article : Google Scholar : PubMed/NCBI
16	Tang FT, Cao Y, Wang TQ, Wang LJ, Guo J, Zhou XS, Xu SW, Liu WH, Liu PQ and Huang HQ: Tanshinone IIA attenuates atherosclerosis in ApoE (^−/−) mice through down-regulation of scavenger receptor expression. Eur J Pharmacol. 650:275–284. 2011. View Article : Google Scholar : PubMed/NCBI
17	Xu S, Little PJ, Lan T, Huang Y, Le K, Wu X, Shen X, Huang H, Cai Y, Tang F, et al: Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet. Arch Biochem Biophys. 515:72–79. 2011. View Article : Google Scholar : PubMed/NCBI
18	Smith JD and Breslow JL: The emergence of mouse models of atherosclerosis and their relevance to clinical research. J Intern Med. 242:99–109. 1997. View Article : Google Scholar : PubMed/NCBI
19	O'Neill TP: Apolipoprotein E-deficient mouse model of human atherosclerosis. Toxicol Pathol. 25:20–1. 1997. View Article : Google Scholar : PubMed/NCBI
20	Basta G, Schmidt AM and De Caterina R: Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 63:582–592. 2004. View Article : Google Scholar : PubMed/NCBI
21	Garvey W, Fathi A, Bigelow F, Carpenter B and Jimenez C: Improved Movat pentachrome stain. Stain Technol. 61:60–62. 1986. View Article : Google Scholar : PubMed/NCBI
22	Llewellyn BD: An improved Sirius red method for amyloid. J Med Lab Technol. 27:308–309. 1970.PubMed/NCBI
23	Jan NJ, Grimm JL, Tran H, Lathrop KL, Wollstein G, Bilonick RA, Ishikawa H, Kagemann L, Schuman JS and Sigal IA: Polarization microscopy for characterizing fiber orientation of ocular tissues. Biomed Opt Express. 6:4705–4718. 2015. View Article : Google Scholar : PubMed/NCBI
24	Hong X, Meng Y and Kalkanis SN: Serum proteins are extracted along with monolayer cells in plasticware and interfere with protein analysis. J Biol Methods. 3:e512016. View Article : Google Scholar : PubMed/NCBI
25	Ahn KS and Aggarwal BB: Transcription factor NF-kappaB: A sensor for smoke and stress signals. Ann N Y Acad Sci. 1056:218–233. 2005. View Article : Google Scholar : PubMed/NCBI
26	Yamamoto Y and Gaynor RB: IkappaB kinases: Key regulators of the NF-kappaB pathway. Trends Biochem Sci. 29:72–79. 2004. View Article : Google Scholar : PubMed/NCBI
27	Chistiakov DA, Sobenin IA and Orekhov AN: Vascular extracellular matrix in atherosclerosis. Cardiol Rev. 21:270–288. 2013. View Article : Google Scholar : PubMed/NCBI
28	Chen Q, Jin M, Yang F, Zhu J, Xiao Q and Zhang L: Matrix metalloproteinases: Inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm. 2013:9283152013. View Article : Google Scholar : PubMed/NCBI
29	Berg G, Miksztowicz V and Schreier L: Metalloproteinases in metabolic syndrome. Clin Chim Acta. 412:1731–1739. 2011. View Article : Google Scholar : PubMed/NCBI
30	De Nooijer R, Verkleij CJ, von der Thüsen JH, Jukema JW, van der Wall EE, van Berkel TJ, Baker AH and Biessen EA: Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesionsbut not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol. 26:340–346. 2006. View Article : Google Scholar : PubMed/NCBI
31	Razansky D, Harlaar NJ, Hillebrands JL, Taruttis A, Herzog E, Zeebregts CJ, van Dam GM and Ntziachristos V: Multispectral optoacoustic tomography of matrix metalloproteinase activity in vulnerable human carotid plaques. Mol Imaging Biol. 14:277–285. 2012. View Article : Google Scholar : PubMed/NCBI
32	Murillo CA, Woodside KJ, Guo Q, Zhang S, O'Connor KL and Hunter GC: Integrin and matrix metalloproteinase expression in human carotid plaque. J Surg Res. 155:157–164. 2009. View Article : Google Scholar : PubMed/NCBI
33	Wang F, Jin XP, Zhu M, Lin XF, Hu XF, Wang WF, Han Z and Huang LZ: Genotype association of C(−735)T Polymorphism of the MMP-2 gene with the risk of carotid atherosclerosis-vulnerable plaque in the Han Chinese population. Vasc Med. 16:13–18. 2011. View Article : Google Scholar : PubMed/NCBI
34	Reiner Z and Tedeschi-Reiner E: New information on the pathophysiology of atherosclerosis. Lijec Vjesn. 123:26–31, (In Croatian). PubMed/NCBI
35	Boyle JJ: Macrophage activation in atherosclerosis: Pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol. 3:63–68. 2005. View Article : Google Scholar : PubMed/NCBI
36	Chen W, Tang F, Xie B, Chen S, Huang H and Liu P: Amelioration of atherosclerosis by tanshinone IIA in hyperlipidemic rabbits through attenuation of oxidative stress. Eur J Pharmacol. 674:359–364. 2012. View Article : Google Scholar : PubMed/NCBI
37	Wei B, You MG, Ling JJ, Wei LL, Wang K, Li WW, Chen T, Du QM and Ji H: Regulation of antioxidant system, lipids and fatty acid β-oxidation contributes to the cardioprotective effect of sodium tanshinone IIA sulphonate in isoproterenol-induced myocardial infarction in rats. Atherosclerosis. 230:148–156. 2013. View Article : Google Scholar : PubMed/NCBI
38	Fukami K, Yamagishi S and Okuda S: Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des. 20:2395–2402. 2014. View Article : Google Scholar : PubMed/NCBI
39	Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, et al: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation. 108:1070–1077. 2003. View Article : Google Scholar : PubMed/NCBI
40	Zhang F, Banker G, Liu X, Suwanabol PA, Lengfeld J, Yamanouchi D, Kent KC and Liu B: The novel function of advanced glycation end products in regulation of MMP-9 production. J Surg Res. 171:871–876. 2011. View Article : Google Scholar : PubMed/NCBI
41	Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, et al: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation. 108:1070–1077. 2003. View Article : Google Scholar : PubMed/NCBI
42	Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, et al: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 106:2827–2835. 2002. View Article : Google Scholar : PubMed/NCBI
43	Saraswathi V and Hasty AH: The role of lipolysis in mediating the proinflammatory effects of very low density lipoproteins in mouseperitoneal macrophages. J Lipid Res. 47:1406–1415. 2006. View Article : Google Scholar : PubMed/NCBI
44	Kim JY, Kim WJ, Kim H, Suk K and Lee WH: The Stimulation of CD147 Induces MMP-9 expression through ERK and NF-kappaB in macrophages: Implicationfor atherosclerosis. Immune Netw. 9:90–97. 2009. View Article : Google Scholar : PubMed/NCBI
45	Yu X, Lin SG, Huang XR, Bacher M, Leng L, Bucala R and Lan HY: Macrophage migration inhibitory factor induces MMP-9 expression in macrophages via the MEK-ERK MAPkinase pathway. J Interferon Cytokine Res. 27:103–109. 2007. View Article : Google Scholar : PubMed/NCBI
46	Lin SJ, Shyue SK, Hung YY, Chen YH, Ku HH, Chen JW, Tam KB and Chen YL: Superoxide dismutase inhibits the expression of vascular cell adhesion molecule-1 and intracellular cell adhesion molecule-1 induced by tumor necrosis factor-alpha in human endothelial cells through the JNK/p38 pathways. Arterioscler Thromb Vasc Biol. 25:334–340. 2005. View Article : Google Scholar : PubMed/NCBI
47	Guo ZJ, Niu HX, Hou FF, Zhang L, Fu N, Nagai R, Lu X, Chen BH, Shan YX, Tian JW, et al: Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal. 10:1699–1712. 2008. View Article : Google Scholar : PubMed/NCBI